18:44 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

Affimed reports Phase Ib/IIa data of AFM13 for cutaneous lymphoma

Affimed N.V. (NASDAQ:AFMD) reported data from three evaluable patients with relapsed or refractory CD30-positive, cutaneous lymphoma in the first dose cohort of a Phase Ib/IIa trial showing that once-weekly 1.5 mg/kg IV AFM13 led to...
18:44 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

Affimed reports Phase Ib data of AFM13 plus Keytruda for Hodgkin's lymphoma

Affimed N.V. (NASDAQ:AFMD) reported data from nine evaluable patients with relapsed or refractory Hodgkin's lymphoma in a Phase Ib trial showing that 7 mg/kg IV AFM13 plus anti-PD-1 mAb Keytruda pembrolizumab from Merck & Co....
19:45 , Jun 12, 2017 |  BC Extra  |  Company News

Celgene gets options to Dragonfly's NK receptor antibodies

Dragonfly Therapeutics Inc. (Cambridge, Mass.) and Celgene Corp. (NASDAQ:CELG) began a five-year collaboration to discover, develop and commercialize candidates to treat hematologic malignancies based on Dragonfly’s TriNKET (Trispecific NK cell Engager Therapies) platform. Celgene will have...
21:59 , Mar 3, 2017 |  BioCentury  |  Emerging Company Profile

Dragonfly’s trinkets

Dragonfly Therapeutics Inc. is developing trispecific antibodies that direct endogenous NK cells toward tumor cells. By targeting two distinct activating receptors on NK cells, plus a tumor antigen, the antibodies could be more potent than...
01:02 , Feb 4, 2017 |  BioCentury  |  Emerging Company Profile

Bispecific simplicity

EpimAb Biotherapeutics Inc. is developing bispecific antibodies designed to be more potent and stable, less immunogenic and easier to manufacture than those made by competing platforms. The company’s Fabs-In-Tandem Immunoglobulin (FIT-Ig) technology retains all four...
00:57 , Jan 26, 2017 |  BC Innovations  |  Translation in Brief

NK cell double take

NK cells are raising interest in immuno-oncology with potential safety benefits and broader activity than their T cell counterparts, but achieving sufficiently high levels of activation is an ongoing challenge. Affimed N.V. (NASDAQ: AFMD) thinks...
22:06 , Jan 6, 2017 |  BC Week In Review  |  Company News

Affimed, MD Anderson deal

Affimed and MD Anderson partnered to develop and commercialize oncology therapeutics combining MD Anderson's NK cell product with Affimed's TandAb immune cell engager technology. The deal includes Affimed's AFM13, a tetravalent bispecific human antibody targeting...
07:00 , Jul 28, 2016 |  BC Innovations  |  Tools & Techniques

Innate harmony

On the heels of cancer immunotherapy's clinical success, NK cells - a long-known but underappreciated component of the innate immune system - are emerging as the hottest new tool to fight cancer, with the potential...
07:00 , Jul 14, 2016 |  BC Innovations  |  Product R&D

Agonistic families

TNF superfamily receptors and their ligands have long been recognized as clinically relevant therapeutic targets for cancer, and dozens of companies are using different therapeutic modalities to target the proteins. Apogenix AG is one of...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Company News

Affimed, Merck deal

Affimed will fund and conduct a Phase Ib trial evaluating its AFM13 with Merck’s melanoma drug Keytruda pembrolizumab to treat relapsed or refractory Hodgkin lymphoma. The trial is expected to begin this half....